Search Results

TIMS-TOF MS) A rapid, tag-free way to purify functional GPCRs tANCHOR fast and cost-effective cell-based immunization

Generation, selection and functional expression: Nanobodies can be obtained by immunizing a camelid and

signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease Identification of immune-related

in glioblastoma activated by acidic extracellular microenvironment Drosophila cytokine GBP2 exerts immune

Deletion of macrophage Gpr101 disrupts their phenotype and function dysregulating host immune responses

"Published: May 10, 2022 To accelerate clinical development of its best-in-class and first-in-class immuno-oncology in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology

In the immune system ORs are expressed in different blood cells where aroma compounds from butter, known

Twice-daily treatment with mOB-004 dose-dependently suppressed monocyte infiltration into the peritoneum PROcisionXᵀᴹ discovery platform Structure-based validation of Orion’s approach Zheng, Y. et al. (2017) Immunity

these PTMs in the chemokine receptor system which may ultimately allow for new precise targeting of the immune

Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company

Discovery Collaboration Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology

Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody Engineering Scientist—Immuno-Oncology

Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody Engineering Scientist—Immuno-Oncology

Domain Therapeutics announces the European Patent Office decision to grant a patent for its proprietary immuno-oncology

manipulation, and potential use of Opn5 and its homologs Industry News The Leading GPCR Company in Immuno-Oncology

Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody Engineering Scientist—Immuno-Oncology

GPCR Jobs NEW Director - Targeted Oncology NEW Senior Scientist - Antibody Engineering NEW Scientist—Immuno-Oncology

strengthens leadership team to spearhead global development and North American expansion as the leading GPCR immuno-oncology

Postdoctoral Researcher Director - Targeted Oncology Senior Scientist - Antibody Engineering Scientist—Immuno-Oncology

Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology